Status:

NOT_YET_RECRUITING

Vitamin C With Steroids for Gastrointestinal GVHD

Lead Sponsor:

Baylor College of Medicine

Collaborating Sponsors:

The Methodist Hospital Research Institute

Center for Cell and Gene Therapy, Baylor College of Medicine

Conditions:

Graft-versus-host-disease (GVHD)

Gastrointestinal

Eligibility:

All Genders

5+ years

Phase:

EARLY_PHASE1

Brief Summary

After a transplant from another donor, one risk is graft versus host disease (GVHD) that happens because of differences between the donated cells (graft) and the patient's body cells (host). The new c...

Detailed Description

Patients enrolled on this trial will receive vitamin C through the vein or by mouth daily for 56 days. This will start at the same time or within 3 days of starting standard treatment for gut GVHD wit...

Eligibility Criteria

Inclusion

  • Patients 5 years of age or older at time of enrollment.
  • Patients experiencing their initial presentation of stage 2 or greater acute LGI GVHD (with or without other organ involvement) or stage 1 LGI + skin aGVHD requiring systemic therapy after allogeneic transplant for any malignant or non-malignant indication using any graft/donor source or conditioning intensity.
  • KPS ≥70%
  • Patients should not have received systemic immune suppressive therapy for treatment of active GVHD except for a maximum of 72 hours of steroid therapy (with or without ruxolitinib) prior to enrollment. Topical skin and GI corticosteroids (such as budesonide and oral beclomethasone diproprionate) are allowed.
  • Informed Consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.

Exclusion

  • Relapsed, progressing or persistent malignancy or evidence of minimal residual disease (MRD) requiring withdrawal of systemic immune suppression.
  • Patients with acute GVHD developing after administration of a donor lymphocyte infusion (DLI) for relapse/progression of disease.
  • Patients with uncontrolled infections will be excluded. Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms
  • Known or suspected hypersensitivity to vitamin C.
  • De novo chronic GVHD or overlap syndrome developing before or present at the time of enrollment.
  • Patients receiving other drugs for the treatment of GVHD except as noted above. GVHD prophylaxis agents (e.g., calcineurin inhibitors) may be continued at local Investigator's discretion.
  • Patients on renal replacement therapy.
  • Patients requiring continuous supplemental oxygen \> 2L/min to maintain peripheral O2 saturation \[SpO2\] \> 90%.
  • Patients with active hepatic sinusoidal obstructive syndrome (SOS) and/or clinical evidence of impaired hepatic function (ascites or encephalopathy related to liver disease.
  • Patients receiving systemic corticosteroids (CS) for any indication within 7 days before enrollment, except the following:
  • Corticosteroids administered as premedication for supportive care (such as before transfusion of blood products or before intravenous medications to prevent infusion reactions, fever, etc.).
  • If steroid therapy has been administered for treatment of a non-GVHD related condition and tapered to \< 0.6 mg/kg/day prednisone (0.5 mg/kg/day methylprednisolone) for 7 or more days prior to enrollment.
  • History of G6PD deficiency, sickle cell disease or hemochromatosis.
  • History of oxalate kidney stones.
  • Patients unlikely to be adherent to study specific assessments at the transplant center.

Key Trial Info

Start Date :

January 1 2026

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2029

Estimated Enrollment :

35 Patients enrolled

Trial Details

Trial ID

NCT07197749

Start Date

January 1 2026

End Date

October 1 2029

Last Update

November 28 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.